The purposes of Biospecimens Accessioning and Processing (BAP) Shared Resource are 1) to provide a central facility to electronically accession biospecimens intended for cancer research, 2) to process the specimens appropriately according to their projected end use, 3) to provide nucleic acid extraction services, and 4) to provide cryopreservation of mononuclear cells and EBV immortalization of B lymphocytes. Specimens accessioned in the shared resource will be linked to the Mayo Life Sciences Warehouse database, so that each specimen will be associated with patient data under Internal Review Board-approved protocols. When appropriate, accessioning also will be linked to the specimen tracking database for storage in a central warehouse freezer. Biospecimens accessioned through this resource include solid tissues as well as whole blood and other bodily fluids. Once accessioned, blood specimens will be processed for nucleic acid extraction, future or immediate EBV immortalization of mononuclear cells, and/or frozen storage as plasma, serum or buffy coats. Other fluids will be aliquoted and stored frozen for future analyses, including proteomics and pharmacokinetics. Fresh solid tissues will be dissected and flash frozen in liquid nitrogen or placed in molds containing freezing medium prior to freezing in a controlled temperature histobath. One of the most valuable contributions of the BAP resource is the specimen annotation that is brought into the Research Biospecimen Database at the time of specimen accessioning. Together, the electronic biospecimen accessioning combined with basic specimen processing, EBV immortalization, and nucleic acid extraction services have created a very powerful, synergistic Shared Resource invaluable for supporting the translational, epidemiologic, and basic research programs for Cancer Center members. Future objectives for this shared resource include 1) developing strategies to routinely collect tissues from all three Mayo sites for future RNA extraction without compromising histology and immunohistochemistry, and 2) expanding to all three Mayo sites the electronic accessioning of specimens into a central Research Biospecimen Database. This collection of biospecimens will allow us to build a unique, valuable resource of highly annotated specimens to support cancer research.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA015083-31
Application #
7125545
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2005-03-01
Budget End
2006-02-28
Support Year
31
Fiscal Year
2005
Total Cost
$168,554
Indirect Cost
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Langlais, Blake T; Geyer, Holly; Scherber, Robyn et al. (2018) Quality of life and symptom burden among myeloproliferative neoplasm patients: do symptoms impact quality of life? Leuk Lymphoma :1-7
Yang, Ju Dong; Addissie, Benyam D; Mara, Kristin C et al. (2018) GALAD Score for Hepatocellular Carcinoma Detection in Comparison to Liver Ultrasound and Proposal of GALADUS Score. Cancer Epidemiol Biomarkers Prev :
Kurmi, Kiran; Hitosugi, Sadae; Yu, Jia et al. (2018) Tyrosine Phosphorylation of Mitochondrial Creatine Kinase 1 Enhances a Druggable Tumor Energy Shuttle Pathway. Cell Metab 28:833-847.e8
O'Mara, Tracy A; Glubb, Dylan M; Amant, Frederic et al. (2018) Identification of nine new susceptibility loci for endometrial cancer. Nat Commun 9:3166
Wallace, Sumer K; Halverson, Jessica W; Jankowski, Christopher J et al. (2018) Optimizing Blood Transfusion Practices Through Bundled Intervention Implementation in Patients With Gynecologic Cancer Undergoing Laparotomy. Obstet Gynecol 131:891-898
Shrestha, Shikshya; Zhang, Cheng; Jerde, Calvin R et al. (2018) Gene-Specific Variant Classifier (DPYD-Varifier) to Identify Deleterious Alleles of Dihydropyrimidine Dehydrogenase. Clin Pharmacol Ther 104:709-718
Hu, G; Dasari, S; Asmann, Y W et al. (2018) Targetable fusions of the FRK tyrosine kinase in ALK-negative anaplastic large cell lymphoma. Leukemia 32:565-569
Geller, James I; Fox, Elizabeth; Turpin, Brian K et al. (2018) A study of axitinib, a VEGF receptor tyrosine kinase inhibitor, in children and adolescents with recurrent or refractory solid tumors: A Children's Oncology Group phase 1 and pilot consortium trial (ADVL1315). Cancer 124:4548-4555
Luchtel, Rebecca A; Dasari, Surendra; Oishi, Naoki et al. (2018) Molecular profiling reveals immunogenic cues in anaplastic large cell lymphomas with DUSP22 rearrangements. Blood 132:1386-1398
Oishi, Naoki; Brody, Garry S; Ketterling, Rhett P et al. (2018) Genetic subtyping of breast implant-associated anaplastic large cell lymphoma. Blood 132:544-547

Showing the most recent 10 out of 1129 publications